DHR vs IDXX
Danaher Corporation and Idexx Laboratories, both Healthcare
Danaher Corporation is the larger company at $125B against $44B. On trailing earnings IDXX is the cheaper of the two at a P/E of 36.4 against 39.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year DHR returned +13% against -21% for IDXX. The RyuScore puts IDXX ahead, 70 against 51 out of 100.
| Figure | DHR | IDXX |
|---|---|---|
| Last close | $220 | $518 |
| Market cap | $125B | $44B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 39.0 | 36.4 |
| 1-year return | +13% | -21% |
| 5-year return | -21% | -21% |
| RyuScoresector-relative, 1–10 | 51/100 | 70/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Danaher Corporation
Revenue of $6.3B in Q2 2026, net income $870M. Its largest reported line is Diagnostics, 46% of the disclosed total.
Idexx Laboratories
Revenue of $1.2B in Q2 2026, net income $338M. Its largest reported line is Vet Lab Consumables, 35% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.